Slide 1: Q1 2025 Earnings
Q1 2025 Earnings Chloe Podder since 2021 May 8, 2025 The Pod has an IP28 rating for up to 25 feet for 60 minutes. The PDM and Controller are not waterproof.
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, and the approval of products by regulatory bodies. These forward-looking statements
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant curr
Slide 4: Q1 2025 Performance
Q1 2025 Performance1 Total Revenue Omnipod Revenue by Geography Other Financial Highlights U.S. Omnipod $401.7M GROSS MARGIN 26.4% 71.9% Total Company Total Omnipod $569.0M $554.1M up 240 bps 28.8% 28.0% ADJUSTED 29.8% constant currency 29.0% constant currency OPERATING MARGIN International Omnipod
Slide 5: Progress Against Our Strategic Objectives
Progress Against Our Strategic Objectives Advance Lead Drive Omnipod 5 Platform with Innovation U.S. Growth in T1D & T2D Access Internationally • Presented RADIANT trial data at • Filled 100% of expanded sales • Launched Omnipod 5 in the ATTD - first RCT to evaluate direct roles following countries
Slide 6: Q1 2025 Commercial Metrics
Q1 2025 Commercial Metrics Delivered NCS Growth: • YoY & QoQ • in U.S. & International • in T1D & T2D OVER OVER OVER OVER 85% 30% 90% 40% U.S. NCS U.S. NCS U.S. International MDI T2D Customer Base with Customer Base with Omnipod 5 Omnipod 5 6 Note: Commercial metrics are directional estimates derive
Slide 7: FY 2025 Guidance
FY 2025 Guidance1 Revenue Guidance2 Margin Guidance Assumptions & Drivers Q2 2025 FY 2025 FY 2025 FY 2025 Continued strong Omnipod 5 Revenue Gross Margin Raise Operating Margin3 adoption globally Revenue Raise 23% - 26% 19% - 22% ~71% ~16.5% U.S. & International annual NCS growth YoY fueled by casca
Slide 8: Appendix
Appendix Insulet
Slide 9: Insulet Abbreviations and Acronyms
Insulet Abbreviations and Acronyms A1c Blood test measures average blood glucose levels over the last 3 months MDI Multiple Daily Injections AID Automated Insulin Delivery NCS New Customer Starts ATTD Advanced Technology & Treatments for Diabetes PDM Personal Device Manager bps Basis Points QoQ Quar
Slide 10: Q1 2025 Revenue & Margin Performance
Q1 2025 Revenue & Margin Performance1,2 $s in Millions Total Revenue Total Omnipod Gross Profit & Margin U.S. Omnipod International Omnipod Operating Income & Margin (adjusted) 2 1. Growth rates are on a YoY basis and are in constant currency. See description of non-GAAP financial measures contained
Slide 11: Historical Financial Performance
Historical Financial Performance $s in Millions Total Revenue1 Total Omnipod1 Gross Profit & Margin (adjusted) 2 2 U.S. Omnipod1 International Omnipod1 Operating Income & Margin (adjusted) 2 2 1. Growth rates are on a YoY basis and are in constant currency. See description of non-GAAP financial meas
Slide 12: Non-GAAP Reconciliation — Revenue Guidance
Non-GAAP Reconciliation — Revenue Guidance Year Ending December 31, 2025 Revenue Growth GAAP Currency Impact Constant Currency U.S. Omnipod 18% to 21% —% 18% to 21% International Omnipod 29% to 32% 2% 27% to 30% Total Omnipod 21% to 24% 1% 20% to 23% Drug Delivery (35)% to (25)% —% (35)% to (25)% To
Slide 13: Reconciliation of Historical Non-GAAP Measures
Reconciliation of Historical Non-GAAP Measures % of FY 2024 Revenue % of FY 2023 Revenue % of FY 2022 Revenue % of FY 2021 Revenue % of Q1'2025 Revenue % of Q1'2024 Revenue Total Revenue GAAP Growth Rate 22.1% 30.0% 18.8% 21.5% 28.8% 23.3% Less: Currency Impact 0.2% 0.4% (3.7)% 1.8% (1.0)% 0.5% Cons